Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease

NCT01893996 is registered in ClinicalTrials.gov with Jonathan Graf as lead sponsor.

NCT NCT01893996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01893996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease
Lead sponsor
Jonathan Graf
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2013
Completion date
July 31, 2017
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disease, rheumatoid arthritis